CEL-SCI CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares.
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-06-30 was 0.00 shares.
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-03-31 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares 10-Q · filed 2026-08-14 | |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-15 | |
| 2025-06-30 | 0.00 shares 10-Q · filed 2026-08-14 | |
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-05-15 | |
| 2022-06-30 | 0.00 shares 10-Q · filed 2022-08-12 | |
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-13 | |
| 2021-12-31 | 6.50K shares 10-Q · filed 2023-02-14 | |
| 2021-06-30 | 72.81K shares 10-Q · filed 2022-08-12 | |
| 2021-03-31 | 48.84K shares 10-Q · filed 2022-05-13 | |
| 2020-12-31 | 5.30K shares 10-Q · filed 2022-02-11 | |
| 2020-06-30 | 73.72K shares 10-Q · filed 2021-08-13 | |
| 2020-03-31 | 20.48K shares 10-Q · filed 2021-05-17 | |
| 2019-06-30 | 42.77K shares 10-Q/A · filed 2020-12-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |